Vivo Ventures Closes $275M Life Science Venture Fund
Palo Alto-based Vivo Ventures has closed a $275M life sciences venture fund, Vivo Ventures Fund VI, L.P., the firm said this morning. The fund continues to follow the same general approach as the firm's prior funds, and is focused on companies developing and commercializing therapeutic products. The new fund will be managed by Frank Kung, Edgar Engleman and Albert Cha. Institutional investors in the fund were not disclosed.
posted on Monday, May 7, 2007
Related companies:
Vivo Capital
Related stories:
> Vivo Ventures Closes $375M Healthcare Fund
> 5AM Ventures Closes $200M Life Sciences Fund
> Vivo Ventures Promotes Two
> Illumina Ventures Gets $230M For First Venture Capital Fund
> Third Rock Ventures Raises $426M Fund, Sets Up Shop In San Francisco
silicontap.com Home